Development asset linked to Biorex Healthcare Pvt in public FDA and regional records.
pharma · Chemotherapy-induced nausea and vomiting
Biorex Healthcare Pvt
Helsinn Birex Pharmaceuticals Ltd
Biorex Healthcare Pvt drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Gurugram, IN HQ
2009 Founded
32 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Gurugram, IN
- Founded
- 2009
- Employees
- 32
- Programs
- 1
- Drugs
- 14
- Patents
- 0
Biorex Healthcare Pvt pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Biorex Healthcare Pvt drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Biorex Healthcare Pvt in public FDA and regional records.
-
fosaprepitant
Alimentary tract and metabolism (A04)Alimentary tract and metabolism (A04) compound in Biorex Healthcare Pvt's portfolio. Mechanism: Neurokinin 1 receptor antagonist.
- Mechanism
- Neurokinin 1 receptor antagonist
-
US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
Development asset linked to Biorex Healthcare Pvt in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Biorex Healthcare Pvt in public FDA and regional records.
-
Development asset linked to Biorex Healthcare Pvt in public FDA and regional records.
-
netupitant
Alimentary tract and metabolism (A04)US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.
- Target
- 5-hydroxytryptamine receptor 3A
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
palonosetron
Alimentary tract and metabolism (A04)Alimentary tract and metabolism (A04) compound in Biorex Healthcare Pvt's portfolio. Mechanism: Serotonin 3a (5-HT3a) receptor antagonist.
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
Development asset linked to Biorex Healthcare Pvt in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Biorex Healthcare Pvt in public FDA and regional records.
-
Development asset linked to Biorex Healthcare Pvt in public FDA and regional records.